Navigation Links
Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
Date:1/28/2009

CAMBRIDGE, England, January 28 /PRNewswire/ -- Phico Therapeutics today announced it has been granted a Wellcome Trust Strategic Translational Award totalling GBP1.03 million to cover Phase I and II trials of its lead candidate SASPject(TM) PT1.2 for nasal decolonisation of MRSA and S. aureus. PT1.2 is based on a new class of antibacterial proteins called SASPs which bind to bacterial DNA resulting in rapid "speed of kill". Phico envisages developing a fast-acting, easily applicable nasal gel which would combat both hospital S. aureus infection and hospital and community MRSA transmission and drug-resistance.

According to Phico Therapeutics CEO and founder, Dr Heather Fairhead, there is a clear need for such a product. "Whilst hospitals have introduced stricter cleaning regimes, the twin problems of transmission and drug-resistance remain. We already demonstrated last year in several studies, including some carried out in conjunction with the UK's Health Protection Agency, that PT1.2 is rapidly bactericidal against more than 200 clinical S. aureus and MRSA isolates, spanning the known MRSA types in Europe and the US. Indeed in the speed of kill assay, SASP caused a greater than or equal to 99.9 % drop in viability within 2 minutes against a 10(5) culture and a greater than or equal to 99.9 % drop in viability within 10 minutes against a 10(7) culture of a major US MRSA strain. I am delighted that the Wellcome Trust see the potential of PT1.2. This award will enable us to conduct phase I and II clinical trials with results expected Q3 2009 and Q3 2010 respectively."

Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust commented: "There is an urgent need to develop innovative ways to manage the transmission of antibiotic-resistant bacteria in the hospital and care-home environments. The approach being taken by Dr Fairhead and colleagues is imaginative and original. If successful, this technology may provide an important new tool in the fight against MRSA and other pathogenic bacteria."

Dr Fairhead also added that other SASP candidates in the Company's pipeline are being developed against C. difficile and E. coli/Klebsiella pneumoniae, and a modified PT1.2 is being developed for intravenous use and that she would be seeking further funding to advance their development.

    Corporate Enquiries
    Heather Fairhead
    CEO
    Tel: +44(0)1223-496562
    Email: hf@phicotherapeutics.co.uk


'/>"/>
SOURCE Phico Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) ... second quarter ended April 1, 2017 .   GAAP ... compared to the prior year period as the sale ... gain, while non-GAAP diluted EPS of $0.50 increased 6.4%.  ... constant currency terms.  Excluding the effects of blood screening ...
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... Agreements being discussed by President Donald Trump and the rest of the world. Donald ... up peace talks in the continuous battle between Israel and Palestine. The world’s eyes ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based ... of proceeds from its 14th Annual Clays for Kids fundraiser, to be held ... Bennett, Colorado. , As part of BluSky’s partnership with The Adoption Exchange, ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee ... a number of critical issues to address before students could return to classes. , ... or no disruption to class schedules. Second, the project had to comply with New ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Dr. Alan I. ... in New York City. He is known for his distinguished expertise and experience ... surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm ...
Breaking Medicine News(10 mins):